Showing 31-40 of 6952 results for "".
SCALE Notes
https://practicaldermatology.com/issues/supplements/scale-notes/22088/News and views from Music City SCALEApproval for Evolus; Remembering Vic Narurkar, MD
https://practicaldermatology.com/topics/practice-management/dermwiretv-approval-for-evolus-remembering-vic-narurkar-md/19553/The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by healBryhali, Xepi Launches; Epionce's New Facility
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-bryhali-xepi-launches-epionce-s-new-facility/18213/Bryhali (halobetasol propionate) 0.01% Lotion from Ortho Dermatologics is now available for the topical treatment of plaque psoriasis in adults. Lawrence J. Green, MD a lead investigator on the Phase 3 studies speaks to DermWireTV. Botanical-based skincare company Epionce has a new 18,500 square fooMedical Derm at Summer AAD; Novel Drugs, Acne at Derm 2018
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-medical-derm-at-summer-aad-novel-drugs-acne-at-derm-2018/18244/The Summer meeting of the American Academy of Dermatology (AAD) gathers members for updates on medical and aesthetic advancements. This year, topics included advanced therapeutics, skin cancer, and skin of color. DERM 2018 provides an opportunity for nurse practitioners and physician assistants in dBrightGuard Covers NYC, Galderma Uncovers Rosacea Burden, Dermira's Qbrexza Approved
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-brightguard-covers-nyc-galderma-uncovers-rosacea-burden-dermira-s-qbrexza-approved/18288/BrightGuard dispensers have now been installed at 53 public pools and 11 beaches in various locations throughout metropolitan New York. The impact of rosacea can be significant for affected patients. According to survey results released last month by Galderma, 86% of patients with rosacea modify theValeant's Siliq Cleared, AmSpa Survey, New Skin Cancer Imaging
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-s-siliq-cleared-amspa-survey-new-skin-cancer-imaging/18527/The FDA has approved Valeant Pharmaceutical's Siliq (brodalumab) injection for subcutaneous use for patients with moderate-to-severe plaque psoriasis. The American Med Spa Association (AmSpa) has extended the deadline for its comprehensive survey of MedSpas nationwide. Multiphoton microscopy of mitoEnstilar Approved; New Data for Otezla, Duac
https://practicaldermatology.com/topics/psoriasis/dermwiretv-enstilar-approved-new-data-for-otezla-duac/18687/LEO Pharma's Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% has been FDA-approved for plaque psoriasis. New data presented at EADV on Stiefel's Duac, Celgene's Otezla, and Boehringer Ingelheim's investigational biologic compound BI 655066. Plus, Galderma's OTC Excipial lNon-genital Warts: A Review of Current Treatments
https://practicaldermatology.com/topics/general-topics/non-genital-warts-a-review-of-current-treatments/21884/When determining which treatment modality to choose for non-genital warts, there are several factors to consider, including the convenience of the treatment, patient discomfort, location of warts, and potential side effects.Dermatology Q&A: New Directions in the Treatment of Hypopigmented Scars
https://practicaldermatology.com/topics/general-topics/dermatology-qa-new-directions-in-the-treatment-of-hypopigmented-scars/21980/A new study shows that off-label use of an unexpected agent yields promising results in the repigmentation of hypopigmented scars.Lasers in Practice: Devices for Non-Invasive Fat Reduction
https://practicaldermatology.com/topics/general-topics/lasers-in-practice-devices-for-non-invasive-fat-reduction/21998/While most devices are investigational, and long-term studies are needed, early evidence is promising for non-invasive fat reduction.